Article Sidebar

PDF
Date Published: 20/07/2021
Abstract Views: 218
Views PDF: 150
DOI: https://doi.org/10.51298/vmj.v501i1.414
Issue
Vol. 501 No. 1 (2021)
Section
Các bài báo
How to Cite
Thị Thái Hoà, N. . (2021). KRAS MUTATION CHARACTERISTICS IN SMALL CELLULAR NON-ACCOUNT CANCER AT K HOSPITAL. Vietnam Medical Journal, 501(1). https://doi.org/10.51298/vmj.v501i1.414

KRAS MUTATION CHARACTERISTICS IN SMALL CELLULAR NON-ACCOUNT CANCER AT K HOSPITAL

Nguyễn Thị Thái Hoà

Main Article Content

Abstract

Objective: To evaluate the KRAS mutation in non-small cell lung cancer patients at K hospital. Objects and methods: Retrospective description of 931 NGS test samples, including 758 tissue samples from non-small cell lung cancer patients at K Hospital from 1/2019. The test is done at HCMCT Genetics Institute using Massively parallel DNA by next generation sequencing technology. Results: KRAS mutation accounted for 20.1%; mainly occurs in men, accounting for 92%. 9% of the KRAS mutation occurs concurrently with another mutation (EGFR, ALK, BRAF, MET. PI3KCA). Mutations in Codon 12 accounted for 81.3%; codon 13 accounts for 18.7%. Conclusion: The KRAS mutation in the K hospital survey is consistent with the data in the literature

Article Details

Keywords

Non-small cell Lung cancer, KRAS mutation

References

1. Anh-thu Huynh Dang, Vu-Uyen tran, Thanh-Truong chan et al. Actionable Mutation Profiles of non-Small cell Lung cancer patients from Vietnamese population. Scientific Reports (2020) 10:2707|https://doi.org/10.1038/s41598-020-59744-3
2. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989; 49:4682–4689. [PubMed] [Google Scholar]
3. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008,455: 1069-1075.
4. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K ras codon 12 mutations in patients with resected stage I and II non-smallcell lung cancer. J Clin Oncol, 1999,17:668-675.
5. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the Kras gene in patients with primary adenocarcinoma of the lung. Cancer, 2001,92: 1525-1230.
6. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer, 2005,92:131-139.
7. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2005,2:e17.
8. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005 Sep 1;23(25):5900-9. doi: 10.1200/JCO.2005.02.857. Epub 2005 Jul 25.PMID: 16043828